Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has raised over 1.1 billion yuan ($151.7 million) in a Series C round of financing from domestic and overseas investors, according to a statement on Thursday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
